These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 12470212

  • 41. Probing the β-pocket of the active site of human liver glycogen phosphorylase with 3-(C-β-d-glucopyranosyl)-5-(4-substituted-phenyl)-1, 2, 4-triazole inhibitors.
    Kyriakis E, Solovou TGA, Kun S, Czifrák K, Szőcs B, Juhász L, Bokor É, Stravodimos GA, Kantsadi AL, Chatzileontiadou DSM, Skamnaki VT, Somsák L, Leonidas DD.
    Bioorg Chem; 2018 Apr; 77():485-493. PubMed ID: 29454281
    [Abstract] [Full Text] [Related]

  • 42. Glycogen phosphorylase inhibitor N-(3,5-dimethyl-Benzoyl)-N'-(β-D-glucopyranosyl)urea improves glucose tolerance under normoglycemic and diabetic conditions and rearranges hepatic metabolism.
    Nagy L, Docsa T, Szántó M, Brunyánszki A, Hegedűs C, Márton J, Kónya B, Virág L, Somsák L, Gergely P, Bai P.
    PLoS One; 2013 Apr; 8(7):e69420. PubMed ID: 23936011
    [Abstract] [Full Text] [Related]

  • 43. The effect of glucose on the potency of two distinct glycogen phosphorylase inhibitors.
    Andersen B, Westergaard N.
    Biochem J; 2002 Oct 15; 367(Pt 2):443-50. PubMed ID: 12099891
    [Abstract] [Full Text] [Related]

  • 44. Design of inhibitors of glycogen phosphorylase: a study of alpha- and beta-C-glucosides and 1-thio-beta-D-glucose compounds.
    Watson KA, Mitchell EP, Johnson LN, Son JC, Bichard CJ, Orchard MG, Fleet GW, Oikonomakos NG, Leonidas DD, Kontou M.
    Biochemistry; 1994 May 17; 33(19):5745-58. PubMed ID: 8180201
    [Abstract] [Full Text] [Related]

  • 45. Glucose analogue inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID force-field and GOLPE variable selection.
    Watson KA, Mitchell EP, Johnson LN, Cruciani G, Son JC, Bichard CJ, Fleet GW, Oikonomakos NG, Kontou M, Zographos SE.
    Acta Crystallogr D Biol Crystallogr; 1995 Jul 01; 51(Pt 4):458-72. PubMed ID: 15299833
    [Abstract] [Full Text] [Related]

  • 46. A new allosteric site in glycogen phosphorylase b as a target for drug interactions.
    Oikonomakos NG, Skamnaki VT, Tsitsanou KE, Gavalas NG, Johnson LN.
    Structure; 2000 Jun 15; 8(6):575-84. PubMed ID: 10873856
    [Abstract] [Full Text] [Related]

  • 47. Design and Synthesis of 3-(β-d-Glucopyranosyl)-4-amino/4-guanidino Pyrazole Derivatives and Analysis of Their Glycogen Phosphorylase Inhibitory Potential.
    Kun S, Mathomes RT, Docsa T, Somsák L, Hayes JM.
    Molecules; 2023 Mar 28; 28(7):. PubMed ID: 37049768
    [Abstract] [Full Text] [Related]

  • 48. Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme.
    Freeman S, Bartlett JB, Convey G, Hardern I, Teague JL, Loxham SJ, Allen JM, Poucher SM, Charles AD.
    Br J Pharmacol; 2006 Nov 28; 149(6):775-85. PubMed ID: 17016495
    [Abstract] [Full Text] [Related]

  • 49. Glucose analogue inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes.
    Martin JL, Veluraja K, Ross K, Johnson LN, Fleet GW, Ramsden NG, Bruce I, Orchard MG, Oikonomakos NG, Papageorgiou AC.
    Biochemistry; 1991 Oct 22; 30(42):10101-16. PubMed ID: 1931942
    [Abstract] [Full Text] [Related]

  • 50. Selective photoregulation of the activity of glycogen synthase and glycogen phosphorylase, two key enzymes in glycogen metabolism.
    Díaz-Lobo M, Garcia-Amorós J, Fita I, Velasco D, Guinovart JJ, Ferrer JC.
    Org Biomol Chem; 2015 Jul 14; 13(26):7282-8. PubMed ID: 26055498
    [Abstract] [Full Text] [Related]

  • 51. An Improved Comparative Docking Approach for Developing Specific Glycogen Phosphorylase Inhibitors Using Pentacyclic Triterpenes.
    Konkimalla VB.
    Curr Top Med Chem; 2017 Jul 14; 17(14):1640-1645. PubMed ID: 27823565
    [Abstract] [Full Text] [Related]

  • 52. van der Waals interactions govern C-β-d-glucopyranosyl triazoles' nM inhibitory potency in human liver glycogen phosphorylase.
    Kantsadi AL, Stravodimos GA, Kyriakis E, Chatzileontiadou DSM, Solovou TGA, Kun S, Bokor É, Somsák L, Leonidas DD.
    J Struct Biol; 2017 Jul 14; 199(1):57-67. PubMed ID: 28483603
    [Abstract] [Full Text] [Related]

  • 53. Binding of beta-D-glucopyranosyl bismethoxyphosphoramidate to glycogen phosphorylase b: kinetic and crystallographic studies.
    Chrysina ED, Kosmopoulou MN, Kardakaris R, Bischler N, Leonidas DD, Kannan T, Loganathan D, Oikonomakos NG.
    Bioorg Med Chem; 2005 Feb 01; 13(3):765-72. PubMed ID: 15653344
    [Abstract] [Full Text] [Related]

  • 54. 2-Oxo-1,2-dihydropyridinyl-3-yl amide-based GPa inhibitors: Design, synthesis and structure-activity relationship study.
    Loughlin WA, Jenkins ID, Karis ND, Schweiker SS, Healy PC.
    Eur J Med Chem; 2016 Mar 23; 111():1-14. PubMed ID: 26851835
    [Abstract] [Full Text] [Related]

  • 55. Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149.
    Lerín C, Montell E, Nolasco T, García-Rocha M, Guinovart JJ, Gómez-Foix AM.
    Biochem J; 2004 Mar 15; 378(Pt 3):1073-7. PubMed ID: 14651477
    [Abstract] [Full Text] [Related]

  • 56. Binding of N-acetyl-N '-beta-D-glucopyranosyl urea and N-benzoyl-N '-beta-D-glucopyranosyl urea to glycogen phosphorylase b: kinetic and crystallographic studies.
    Oikonomakos NG, Kosmopoulou M, Zographos SE, Leonidas DD, Chrysina ED, Somsák L, Nagy V, Praly JP, Docsa T, Tóth B, Gergely P.
    Eur J Biochem; 2002 Mar 15; 269(6):1684-96. PubMed ID: 11895439
    [Abstract] [Full Text] [Related]

  • 57. A multidisciplinary study of 3-(β-d-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors: Computation, synthesis, crystallography and kinetics reveal new potent inhibitors.
    Kun S, Begum J, Kyriakis E, Stamati ECV, Barkas TA, Szennyes E, Bokor É, Szabó KE, Stravodimos GA, Sipos Á, Docsa T, Gergely P, Moffatt C, Patraskaki MS, Kokolaki MC, Gkerdi A, Skamnaki VT, Leonidas DD, Somsák L, Hayes JM.
    Eur J Med Chem; 2018 Mar 10; 147():266-278. PubMed ID: 29453094
    [Abstract] [Full Text] [Related]

  • 58. Glucose-based spiro-oxathiazoles as in vivo anti-hyperglycemic agents through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Czifrák K, Larini P, Demontrond F, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Docsa T, Gergely P, Somsák L, Praly JP, Azay-Milhau J, Vidal S.
    Org Biomol Chem; 2020 Feb 07; 18(5):931-940. PubMed ID: 31922157
    [Abstract] [Full Text] [Related]

  • 59. Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle.
    Baker DJ, Timmons JA, Greenhaff PL.
    Diabetes; 2005 Aug 07; 54(8):2453-9. PubMed ID: 16046314
    [Abstract] [Full Text] [Related]

  • 60. Biochemical and biological assessment of the inhibitory potency of extracts from vinification byproducts of Vitis vinifera extracts against glycogen phosphorylase.
    Kantsadi AL, Apostolou A, Theofanous S, Stravodimos GA, Kyriakis E, Gorgogietas VA, Chatzileontiadou DS, Pegiou K, Skamnaki VT, Stagos D, Kouretas D, Psarra AM, Haroutounian SA, Leonidas DD.
    Food Chem Toxicol; 2014 May 07; 67():35-43. PubMed ID: 24556570
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.